JP6770507B2 - ユビキチン化阻害物質として有用なキノリン誘導体 - Google Patents

ユビキチン化阻害物質として有用なキノリン誘導体 Download PDF

Info

Publication number
JP6770507B2
JP6770507B2 JP2017507968A JP2017507968A JP6770507B2 JP 6770507 B2 JP6770507 B2 JP 6770507B2 JP 2017507968 A JP2017507968 A JP 2017507968A JP 2017507968 A JP2017507968 A JP 2017507968A JP 6770507 B2 JP6770507 B2 JP 6770507B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
quinoline
benzenesulfonamide
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017507968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524017A5 (enExample
JP2017524017A (ja
Inventor
デビッド キャロル
デビッド キャロル
アービンダー シュラン
アービンダー シュラン
ラジンデル シン
ラジンデル シン
チアンイン ファン
チアンイン ファン
リューベン ツェートコフ
リューベン ツェートコフ
サルキズ イサカニ
サルキズ イサカニ
ドナルド パヤン
ドナルド パヤン
シモン ショー
シモン ショー
Original Assignee
ライジェル ファーマシューティカルズ， インコーポレイテッド
ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ， インコーポレイテッド, ライジェル ファーマシューティカルズ， インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017524017A publication Critical patent/JP2017524017A/ja
Publication of JP2017524017A5 publication Critical patent/JP2017524017A5/ja
Application granted granted Critical
Publication of JP6770507B2 publication Critical patent/JP6770507B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017507968A 2014-08-14 2015-08-14 ユビキチン化阻害物質として有用なキノリン誘導体 Expired - Fee Related JP6770507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037449P 2014-08-14 2014-08-14
US62/037,449 2014-08-14
PCT/US2015/045174 WO2016025779A1 (en) 2014-08-14 2015-08-14 Quinoline derivatives useful as ubiquitination inhibitors

Publications (3)

Publication Number Publication Date
JP2017524017A JP2017524017A (ja) 2017-08-24
JP2017524017A5 JP2017524017A5 (enExample) 2018-09-27
JP6770507B2 true JP6770507B2 (ja) 2020-10-14

Family

ID=53938449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507968A Expired - Fee Related JP6770507B2 (ja) 2014-08-14 2015-08-14 ユビキチン化阻害物質として有用なキノリン誘導体

Country Status (5)

Country Link
US (1) US10040766B2 (enExample)
EP (1) EP3180328B1 (enExample)
JP (1) JP6770507B2 (enExample)
CA (1) CA2958142A1 (enExample)
WO (1) WO2016025779A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7198221B2 (ja) * 2017-04-20 2022-12-28 ゴーダーヴァリ バイオリファイナリーズ リミテッド 抗癌化合物
US11213701B2 (en) * 2018-12-01 2022-01-04 Russell Dahl Neuroprotective quinoline sulfonamides
EP4291555A1 (en) * 2021-02-09 2023-12-20 Celgene Corporation Sulfonamides and their use for treatment of helminthic infections and diseases
CN117865886B (zh) * 2024-03-07 2024-05-10 中国药科大学 一种n-(喹啉-8-基)喹啉-8-磺酰胺类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651595A2 (en) * 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
WO2009137597A1 (en) * 2008-05-06 2009-11-12 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
US20120214803A1 (en) * 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
WO2012122534A2 (en) 2011-03-10 2012-09-13 The Trustees Of Columbia University In The City Of New York N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammation
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
WO2013052943A2 (en) * 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Small molecule inhibitors of mcl-1 and uses thereof

Also Published As

Publication number Publication date
EP3180328B1 (en) 2020-03-18
CA2958142A1 (en) 2016-02-18
JP2017524017A (ja) 2017-08-24
US10040766B2 (en) 2018-08-07
US20160068490A1 (en) 2016-03-10
WO2016025779A1 (en) 2016-02-18
EP3180328A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
CN114901661B (zh) 新型K-Ras G12C抑制剂
KR102868485B1 (ko) Cdk7 키나아제 억제제로서의 화합물 및 이의 용도
WO2021121367A1 (en) Kras mutant protein inhibitors
EP3795570B1 (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
CN120699028A (zh) Nek7激酶的抑制剂
JP6966425B2 (ja) 抗がん剤としての複素環式の限定された三環系スルホンアミド
EP3390374A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP6770507B2 (ja) ユビキチン化阻害物質として有用なキノリン誘導体
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
JP2021185203A (ja) チロシンキナーゼ阻害剤
KR20230043885A (ko) 트리시클릭 헤테로사이클
JP7475370B2 (ja) ブルトン型チロシンキナーゼ阻害剤としての置換されている１－アミノ－１ｈ－イミダゾール－５－カルボキサミド
JP7793763B2 (ja) Ｔｙｋ２／ｊａｋ１シュードキナーゼドメイン阻害剤としての化合物ならびに合成および使用方法
TW201400458A (zh) （２－雜芳基胺基）琥珀酸衍生物
CN111683936B (zh) 多取代苯环化合物、制备方法及其用途
JP2021525755A (ja) チロシンキナーゼ阻害剤として有用なキノリン誘導体
CN121127472A (zh) 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
EP4644376A1 (en) New phenylquinolone compound having antibacterial and anti-cancer functions and preparation thereof
HK40090211A (en) Compound used as ret kinase inhibitor and application thereof
WO2025113519A1 (zh) 内酰胺环类化合物及其用途
HK40041475B (en) Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
WO2025167814A1 (zh) 作为DGKζ抑制剂的化合物
CN117886805A (zh) FabI酶抑制剂及其制备方法和应用
HK40090211B (en) Compound used as ret kinase inhibitor and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200925

R150 Certificate of patent or registration of utility model

Ref document number: 6770507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees